Vinay Prasad's Comeback To FDA Sparks Debate Over Regulatory Direction

FDA Expands Surprise Inspections At Foreign Food And Drug Plants

In a stunning reversal, Dr. Vinay Prasad is returning to his role as director of the U.S. Food and Drug Administration’s (FDA) Center for Biologics Evaluation and Research (CBER), just days after his resignation.

The abrupt departure of the controversial figure, who had been a vocal critic of the biopharmaceutical industry and certain FDA approval pathways, sent ripples through the biotech world.